The drugmaker Ely Lilly ( LLY -4.93%) has had a very successful run over the long run. Shares currently trade around $818 and are up 20,030% over the past 40 years. The stock has also performed well ...

Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales ...

After Eli Lilly raised its guidance in the second quarter, it now actually had to lower its guidance a bit. For the full year of fiscal 2024, Eli Lilly is now expecting revenue to be between $45.4 ...

Below, I'm going to break down Lilly's latest milestone and explain why I see now as a great opportunity to scoop up shares. Back in September, Lilly received FDA approval for its atopic ...

Even a juggernaut like Eli Lilly (NYSE: LLY) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat, ...